Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E39.62 EPS (ttm)0.48 Insider Own1.00% Shs Outstand309.12M Perf Week-2.22%
Market Cap5.82B Forward P/E45.73 EPS next Y0.42 Insider Trans-9.12% Shs Float302.96M Perf Month-15.98%
Income152.10M PEG0.86 EPS next Q-0.08 Inst Own84.90% Short Float4.50% Perf Quarter-8.18%
Sales957.80M P/S6.08 EPS this Y-53.80% Inst Trans0.94% Short Ratio6.34 Perf Half Y-16.05%
Book/sh5.99 P/B3.17 EPS next Y130.56% ROA7.60% Target Price30.85 Perf Year10.67%
Cash/sh3.87 P/C4.90 EPS next 5Y46.00% ROE8.50% 52W Range13.67 - 27.80 Perf YTD7.72%
Dividend- P/FCF18.75 EPS past 5Y22.50% ROI17.30% 52W High-31.73% Beta1.20
Dividend %- Quick Ratio6.90 Sales past 5Y107.60% Gross Margin96.10% 52W Low38.84% ATR0.79
Employees617 Current Ratio7.00 Sales Q/Q-14.90% Oper. Margin17.00% RSI (14)37.44 Volatility3.74% 3.98%
OptionableYes Debt/Eq0.00 EPS Q/Q-133.60% Profit Margin15.90% Rel Volume0.62 Prev Close18.84
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout0.00% Avg Volume2.15M Price18.98
Recom2.00 SMA20-3.59% SMA50-12.18% SMA200-13.79% Volume1,329,015 Change0.74%
Mar-04-20Initiated Barclays Overweight $26
Jan-13-20Initiated SunTrust Buy $31
Nov-13-19Initiated BofA/Merrill Buy $22
Mar-18-19Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-17-18Initiated Goldman Neutral $22
Sep-10-18Initiated Morgan Stanley Underweight $19
May-11-18Reiterated Needham Buy $33 → $30
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Dec-05-20 11:32AM  
Dec-02-20 08:00AM  
Nov-27-20 08:00AM  
05:51AM  
Nov-23-20 05:30PM  
Nov-11-20 08:24AM  
Nov-06-20 03:01PM  
10:33AM  
07:50AM  
Nov-05-20 08:30PM  
04:05PM  
03:45PM  
Nov-03-20 12:46PM  
06:32AM  
05:51AM  
Nov-02-20 04:05PM  
Oct-29-20 12:34PM  
Oct-28-20 06:57AM  
04:38AM  
Oct-27-20 08:24AM  
01:02AM  
Oct-26-20 08:00AM  
Oct-22-20 04:05PM  
Oct-20-20 10:57AM  
Oct-19-20 04:27PM  
06:59AM  
Oct-17-20 06:06AM  
Oct-13-20 09:12AM  
07:49AM  
Oct-09-20 03:02AM  
03:01AM  
Oct-07-20 07:21AM  
Oct-06-20 02:23PM  
Oct-03-20 06:55AM  
Oct-02-20 05:51AM  
Sep-21-20 10:20AM  
05:51AM  
Sep-19-20 12:30PM  
Sep-18-20 06:05PM  
Sep-15-20 08:00AM  
Sep-14-20 08:00AM  
Sep-13-20 06:52AM  
Sep-09-20 12:44PM  
Sep-08-20 11:57PM  
04:05PM  
11:41AM  
08:05AM  
08:01AM  
Sep-05-20 11:31AM  
Aug-25-20 10:02AM  
07:57AM  
Aug-24-20 08:00AM  
Aug-07-20 10:32AM  
Aug-06-20 08:20PM  
04:05PM  
Jul-30-20 12:33PM  
Jul-29-20 04:05PM  
Jul-23-20 12:20PM  
Jul-22-20 12:32PM  
11:40AM  
Jul-21-20 12:10PM  
10:00AM  
Jul-20-20 12:43PM  
08:00AM  
Jul-13-20 10:45AM  
Jul-10-20 07:16AM  
05:51AM  
Jul-03-20 12:36PM  
Jun-30-20 08:00AM  
Jun-22-20 11:02PM  
Jun-18-20 04:05PM  
Jun-17-20 01:42PM  
Jun-12-20 10:15AM  
Jun-11-20 08:00AM  
Jun-04-20 11:31AM  
Jun-03-20 04:05PM  
Jun-02-20 02:59AM  
May-28-20 06:58AM  
May-20-20 01:30PM  
May-13-20 05:00PM  
09:54AM  
May-06-20 04:05PM  
11:40AM  
01:01AM  
May-05-20 06:25PM  
04:05PM  
03:00PM  
May-01-20 01:14PM  
Apr-28-20 12:33PM  
Apr-22-20 10:30AM  
09:00AM  
Apr-21-20 04:05PM  
12:59PM  
12:43PM  
Apr-20-20 06:01PM  
04:19PM  
11:03AM  
07:12AM  
06:59AM  
06:59AM  
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, and other kinases implicated in growth and spread of cancer. It has collaboration and license agreement with Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., Roche, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Daiichi Sankyo Company, Limited, and clinical collaboration with Ipsen. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WILLSEY LANCEDirectorDec 04Option Exercise5.82106,142617,746474,415Dec 04 07:56 PM
MARCHESI VINCENT TDirectorNov 24Option Exercise5.8240,004232,823130,216Nov 25 07:46 PM
MARCHESI VINCENT TDirectorNov 24Sale18.5040,004740,07490,212Nov 25 07:46 PM
Hessekiel JeffreyEVP and General CounselNov 15Option Exercise7.2730,000218,100494,254Nov 17 08:00 PM
WYSZOMIERSKI JACK LDirectorNov 10Option Exercise5.8262,403363,185231,809Nov 13 08:18 PM
WYSZOMIERSKI JACK LDirectorNov 10Sale20.6134,000700,740197,809Nov 13 08:18 PM
Hessekiel JeffreyEVP and General CounselOct 21Option Exercise7.2739,742288,924382,768Oct 23 08:08 PM
Hessekiel JeffreyEVP and General CounselOct 21Sale21.9539,742872,337343,026Oct 23 08:08 PM
Senner Christopher J.EVP and CFOOct 08Option Exercise3.6610,00036,600137,882Oct 09 08:04 PM
Senner Christopher J.EVP and CFOOct 08Sale25.0010,000250,000127,882Oct 09 08:04 PM
Hessekiel JeffreyEVP and General CounselSep 22Option Exercise7.2710,25874,576353,284Sep 24 08:03 PM
Hessekiel JeffreyEVP and General CounselSep 22Sale26.1410,258268,144343,026Sep 24 08:03 PM
Haley Patrick J.EVP, CommercialSep 21Option Exercise5.824,68027,238120,251Sep 23 08:12 PM
Haley Patrick J.EVP, CommercialSep 21Sale26.094,680122,101115,571Sep 23 08:12 PM
Hessekiel JeffreyEVP and General CounselSep 16Option Exercise7.2720,000145,400363,026Sep 16 08:24 PM
Hessekiel JeffreyEVP and General CounselSep 16Sale26.1120,000522,200343,026Sep 16 08:24 PM
Senner Christopher J.EVP and CFOSep 15Option Exercise3.6620,00073,200147,882Sep 15 08:03 PM
Senner Christopher J.EVP and CFOSep 15Sale25.0020,000500,000127,882Sep 15 08:03 PM
Hessekiel JeffreyEVP and General CounselSep 08Option Exercise5.18249,6921,293,315503,692Sep 10 08:39 PM
COHEN CHARLESDirectorSep 01Option Exercise5.82115,396671,605181,375Sep 03 08:05 PM
POSTE GEORGEDirectorAug 14Option Exercise5.8229,662172,633157,992Aug 14 07:50 PM
MORRISSEY MICHAELPresident and CEOJul 20Option Exercise6.21100,000621,000185,985Jul 22 07:06 PM
Haley Patrick J.EVP, CommercialJul 20Sale25.363,15179,909112,189Jul 22 07:01 PM
MORRISSEY MICHAELPresident and CEOJul 10Option Exercise6.21100,000621,000185,985Jul 10 08:48 PM
MORRISSEY MICHAELPresident and CEOJun 19Option Exercise6.21100,000621,000185,985Jun 19 09:20 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 08Option Exercise5.5126,000143,260152,531Jun 10 08:19 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 08Sale22.5626,000586,560126,531Jun 10 08:19 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJun 04Option Exercise1.70100,000170,000425,963Jun 05 08:00 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJun 04Sale22.96100,0002,296,000325,963Jun 05 08:00 PM
MORRISSEY MICHAELPresident and CEOMay 29Option Exercise6.21100,000621,000185,985May 29 09:36 PM
Garber Alan MDirectorMay 22Sale24.4236,111881,83112,718May 22 08:53 PM
MARCHESI VINCENT TDirectorMay 21Option Exercise5.8240,000232,800130,212May 22 09:11 PM
MARCHESI VINCENT TDirectorMay 21Sale24.6440,000985,60090,212May 22 09:11 PM
Haley Patrick J.EVP, CommercialMay 20Sale24.993,15178,743115,340May 22 08:17 PM
WILLSEY LANCEDirectorMay 18Option Exercise4.5830,000137,400398,273May 20 08:36 PM
WILLSEY LANCEDirectorMay 18Sale26.2630,000787,800368,273May 20 08:36 PM
SCANGOS GEORGE ADirectorMay 18Sale25.9675,0001,947,000714,717May 20 08:35 PM
SCANGOS GEORGE ADirectorMay 15Option Exercise5.1051,686263,613789,717May 15 08:31 PM
MORRISSEY MICHAELPresident and CEOMay 15Option Exercise6.21100,000621,000185,985May 15 09:29 PM
WILLSEY LANCEDirectorMay 14Option Exercise5.9215,00088,800383,273May 15 08:19 PM
WILLSEY LANCEDirectorMay 14Sale25.2615,000378,900368,273May 15 08:19 PM
Hessekiel JeffreyEVP and General CounselMay 13Option Exercise1.7025,00042,500264,188May 15 08:20 PM
PAPADOPOULOS STELIOSDirectorMay 13Option Exercise5.82120,791703,0041,173,359May 15 08:18 PM
Hessekiel JeffreyEVP and General CounselMay 11Option Exercise1.9038,00672,211277,194May 11 08:36 PM
MARCHESI VINCENT TDirectorMay 11Option Exercise4.5830,000137,400112,484May 13 09:16 PM
MARCHESI VINCENT TDirectorMay 11Sale26.3030,000789,00082,484May 13 09:16 PM
Hessekiel JeffreyEVP and General CounselMay 11Sale27.0938,0061,029,583239,188May 11 08:36 PM
Haley Patrick J.EVP, CommercialMay 08Option Exercise1.7621,37537,620139,866May 08 09:16 PM
PAPADOPOULOS STELIOSDirectorMay 08Option Exercise5.0345,000226,2001,097,568May 08 09:18 PM
Senner Christopher J.EVP and CFOMay 08Option Exercise3.6678,583287,614199,286May 08 09:22 PM
Hessekiel JeffreyEVP and General CounselMay 08Option Exercise1.9025,00047,500264,188May 11 08:36 PM
Hessekiel JeffreyEVP and General CounselMay 08Sale26.0425,000651,000239,188May 11 08:36 PM
Senner Christopher J.EVP and CFOMay 08Sale25.8178,5832,028,227120,703May 08 09:22 PM
Haley Patrick J.EVP, CommercialMay 08Sale25.8721,375552,971118,491May 08 09:16 PM
PAPADOPOULOS STELIOSDirectorMay 08Sale25.8445,0001,162,8001,052,568May 08 09:18 PM
Lamb PeterEVP, Scientific Strategy & CSOMay 07Option Exercise5.5150,000275,500176,531May 08 09:11 PM
POSTE GEORGEDirectorMay 07Option Exercise5.8230,000174,600142,792May 08 09:13 PM
FELDBAUM CARL BDirectorMay 07Option Exercise4.2731,546134,79840,067May 08 09:14 PM
Senner Christopher J.EVP and CFOMay 07Option Exercise3.6621,41778,386142,120May 08 09:22 PM
Hessekiel JeffreyEVP and General CounselMay 07Option Exercise1.9030,00057,000269,188May 11 08:36 PM
Hessekiel JeffreyEVP and General CounselMay 07Sale25.6130,000768,300239,188May 11 08:36 PM
Senner Christopher J.EVP and CFOMay 07Sale25.8021,417552,559120,703May 08 09:22 PM
FELDBAUM CARL BDirectorMay 07Sale25.0231,546789,2818,521May 08 09:14 PM
POSTE GEORGEDirectorMay 07Sale25.6130,000768,300112,792May 08 09:13 PM
Lamb PeterEVP, Scientific Strategy & CSOMay 07Sale25.5450,0001,277,000126,531May 08 09:11 PM
MORRISSEY MICHAELPresident and CEOMay 06Option Exercise1.70285,284484,983371,269May 08 09:10 PM
MORRISSEY MICHAELPresident and CEOApr 27Option Exercise1.70285,000484,500370,985Apr 29 08:10 PM
SCANGOS GEORGE ADirectorApr 24Sale26.2415,000393,600738,031Apr 24 08:24 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 23Option Exercise1.70100,000170,000425,122Apr 24 08:25 PM
Haley Patrick J.EVP, CommercialApr 23Option Exercise1.705,0008,500121,873Apr 24 08:22 PM
MORRISSEY MICHAELPresident and CEOApr 23Option Exercise5.51250,0001,377,500335,985Apr 24 08:41 PM
SCANGOS GEORGE ADirectorApr 23Sale25.99100,0002,598,635753,031Apr 24 08:24 PM
Haley Patrick J.EVP, CommercialApr 23Sale26.005,000130,000116,873Apr 24 08:22 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 23Sale26.00100,0002,600,000325,122Apr 24 08:25 PM
SCANGOS GEORGE ADirectorApr 22Sale25.054,200105,210853,031Apr 22 08:50 PM
MORRISSEY MICHAELPresident and CEOApr 21Option Exercise5.51220,0001,212,200393,064Apr 22 09:53 PM
SCANGOS GEORGE ADirectorApr 21Sale25.045,800145,232857,231Apr 22 08:50 PM
MORRISSEY MICHAELPresident and CEOApr 20Option Exercise5.51240,0001,322,400325,985Apr 22 09:53 PM
Haley Patrick J.EVP, CommercialApr 20Option Exercise1.705,0008,500121,873Apr 22 08:49 PM
SCANGOS GEORGE ADirectorApr 20Sale23.8950,0001,194,637863,031Apr 22 08:50 PM
Haley Patrick J.EVP, CommercialApr 20Sale24.005,000120,000116,873Apr 22 08:49 PM
SCANGOS GEORGE ADirectorApr 15Sale18.3125,000457,750913,031Apr 17 08:11 PM
SCANGOS GEORGE ADirectorApr 08Sale18.357,065129,643938,031Apr 09 08:20 PM
SCANGOS GEORGE ADirectorApr 07Sale18.2516,435299,939945,096Apr 09 08:20 PM
Lamb PeterEVP, Scientific Strategy & CSOApr 06Option Exercise5.5150,000275,500176,531Apr 08 08:12 PM
Lamb PeterEVP, Scientific Strategy & CSOApr 06Sale17.2650,000863,000126,531Apr 08 08:12 PM
WYSZOMIERSKI JACK LDirectorApr 03Option Exercise5.0345,000226,200175,526Apr 03 08:38 PM
WYSZOMIERSKI JACK LDirectorApr 03Sale16.5713,848229,461161,678Apr 03 08:38 PM
SCANGOS GEORGE ADirectorMar 31Sale18.061,50027,090961,531Apr 02 08:08 PM
Haley Patrick J.EVP, CommercialMar 20Sale15.374,31866,368116,873Mar 20 09:03 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMar 04Option Exercise1.70100,000170,000425,122Mar 06 08:01 PM
MORRISSEY MICHAELPresident and CEOMar 04Option Exercise5.5150,000275,500135,985Mar 06 08:07 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMar 04Sale19.40100,0001,940,000325,122Mar 06 08:01 PM
FELDBAUM CARL BDirectorMar 03Option Exercise5.6238,000213,72046,521Mar 05 08:00 PM
FELDBAUM CARL BDirectorMar 03Sale18.8438,000716,0138,521Mar 05 08:00 PM
COHEN CHARLESDirectorFeb 28Option Exercise5.0345,000226,20065,979Mar 02 09:14 PM
MORRISSEY MICHAELPresident and CEOFeb 26Option Exercise5.5125,000137,750110,985Feb 28 08:05 PM
MORRISSEY MICHAELPresident and CEOFeb 26Sale18.9125,000472,85085,985Feb 28 08:05 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 19Option Exercise5.5140,000220,400365,122Feb 21 08:00 PM
MORRISSEY MICHAELPresident and CEOFeb 19Option Exercise0.0025,0000110,985Feb 21 08:03 PM
IQV IQVIA Holdings Inc. daily Stock Chart
IQV [NYSE]
IQVIA Holdings Inc.
IndexS&P 500 P/E189.99 EPS (ttm)0.90 Insider Own0.40% Shs Outstand191.30M Perf Week1.07%
Market Cap32.14B Forward P/E21.72 EPS next Y7.85 Insider Trans-80.99% Shs Float189.70M Perf Month-0.17%
Income176.00M PEG14.14 EPS next Q2.01 Inst Own92.20% Short Float1.02% Perf Quarter6.49%
Sales10.96B P/S2.93 EPS this Y-11.10% Inst Trans-0.16% Short Ratio1.88 Perf Half Y13.74%
Book/sh30.56 P/B5.58 EPS next Y24.15% ROA0.80% Target Price198.78 Perf Year17.38%
Cash/sh8.19 P/C20.83 EPS next 5Y13.44% ROE3.10% 52W Range81.79 - 180.77 Perf YTD10.42%
Dividend- P/FCF26.45 EPS past 5Y-18.80% ROI3.60% 52W High-5.62% Beta1.41
Dividend %- Quick Ratio1.10 Sales past 5Y15.20% Gross Margin34.00% 52W Low108.60% ATR4.29
Employees67000 Current Ratio1.10 Sales Q/Q0.60% Oper. Margin5.40% RSI (14)53.94 Volatility2.06% 2.31%
OptionableYes Debt/Eq2.13 EPS Q/Q81.00% Profit Margin1.60% Rel Volume1.45 Prev Close167.63
ShortableYes LT Debt/Eq2.11 EarningsOct 20 BMO Payout0.00% Avg Volume1.03M Price170.61
Recom1.80 SMA200.19% SMA503.42% SMA20015.74% Volume1,485,919 Change1.78%
Jul-07-20Initiated Stephens Equal-Weight $150
Mar-02-20Initiated Deutsche Bank Buy $190
Jan-08-20Initiated Wells Fargo Overweight $180
Jan-07-20Initiated Citigroup Buy $185
Dec-13-19Upgrade CFRA Sell → Hold
Nov-14-19Upgrade Wolfe Research Peer Perform → Outperform
Jun-21-19Upgrade Mizuho Neutral → Buy $150 → $175
May-28-19Initiated SVB Leerink Outperform
Jan-18-19Upgrade Jefferies Hold → Buy
Oct-09-18Initiated UBS Buy
Oct-02-18Reiterated Robert W. Baird Outperform $143 → $146
Jul-25-18Upgrade BofA/Merrill Neutral → Buy
Jul-25-18Reiterated Stifel Buy $128 → $150
Jul-03-18Upgrade Raymond James Outperform → Strong Buy
Apr-13-18Upgrade Goldman Neutral → Buy
Mar-07-18Upgrade SunTrust Hold → Buy
Jan-19-18Initiated Evercore ISI Outperform $112
Nov-19-20 11:30AM  
Nov-10-20 09:43AM  
Nov-05-20 09:35AM  
09:32AM  
Nov-02-20 08:00AM  
Oct-23-20 09:35AM  
Oct-20-20 03:00PM  
01:27PM  
10:58AM  
08:25AM  
07:16AM  
07:00AM  
Oct-19-20 10:14AM  
08:34AM  
Oct-15-20 10:00AM  
Oct-13-20 12:30PM  
08:58AM  
Oct-12-20 08:00AM  
Oct-07-20 04:15PM  
Oct-06-20 08:00AM  
Sep-23-20 09:46AM  
Sep-14-20 08:10AM  
Aug-31-20 01:45PM  
08:58AM  
Aug-26-20 02:59PM  
Aug-21-20 11:30AM  
10:54AM  
Aug-08-20 03:04PM  
Aug-05-20 08:00AM  
Aug-04-20 08:00AM  
Jul-31-20 11:09AM  
Jul-30-20 11:40AM  
Jul-29-20 08:00AM  
Jul-25-20 10:39AM  
Jul-23-20 08:00AM  
Jul-22-20 01:00PM  
10:18AM  
10:09AM  
08:25AM  
07:58AM  
07:30AM  
07:00AM  
Jul-21-20 06:12PM  
06:00PM  
06:00PM  
Jul-20-20 08:01AM  
Jul-17-20 11:27AM  
Jul-15-20 12:31PM  
Jul-14-20 11:07AM  
08:00AM  
Jul-08-20 04:15PM  
03:22PM  
Jul-02-20 08:00AM  
Jun-23-20 06:14PM  
Jun-09-20 09:24AM  
Jun-03-20 08:00AM  
Jun-02-20 10:58AM  
Jun-01-20 10:07AM  
May-28-20 01:18PM  
11:31AM  
May-27-20 07:14PM  
May-26-20 03:54PM  
May-21-20 08:00AM  
May-20-20 08:00AM  
May-11-20 10:08AM  
May-07-20 11:52AM  
May-01-20 08:36AM  
Apr-29-20 09:20AM  
Apr-28-20 06:01PM  
12:07PM  
11:01AM  
09:27AM  
08:25AM  
07:00AM  
Apr-27-20 09:43AM  
07:03AM  
Apr-24-20 12:28PM  
Apr-23-20 05:49AM  
Apr-22-20 03:04PM  
Apr-07-20 09:28AM  
Apr-06-20 07:00PM  
Apr-03-20 03:00PM  
10:11AM  
07:02AM  
Apr-02-20 08:29PM  
02:54PM  
Mar-26-20 01:15PM  
Mar-24-20 08:00AM  
Mar-13-20 11:30AM  
Mar-12-20 12:41PM  
Mar-09-20 03:34PM  
Mar-07-20 10:31AM  
10:10AM  
Feb-24-20 02:59PM  
Feb-20-20 08:49AM  
Feb-19-20 06:56AM  
06:23AM  
Feb-17-20 06:31PM  
05:21AM  
Feb-13-20 04:41PM  
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rittenmeyer Ronald ADirectorNov 24Sale172.969,5901,658,68611,894Nov 25 05:03 PM
Rittenmeyer Ronald ADirectorNov 16Sale174.3540,7927,112,08521,484Nov 18 05:03 PM
BOUSBIB ARISee RemarksOct 12Sale170.0069,12011,750,400652,035Oct 14 05:05 PM
BOUSBIB ARISee RemarksSep 15Sale164.3646,0807,573,709652,035Sep 17 05:06 PM
BOUSBIB ARISee RemarksAug 14Sale161.6669,12011,173,939652,035Aug 18 05:03 PM
STAUB W RICHARDSee RemarksAug 07Option Exercise87.2033,8902,955,12732,877Aug 11 05:02 PM
STAUB W RICHARDSee RemarksAug 07Sale160.3220,3673,265,33212,470Aug 11 05:02 PM
Bruehlman Ronald ESee RemarksAug 04Buy159.9410,0001,599,40026,751Aug 05 05:02 PM
TPG Group Holdings (SBS) AdvisFormer DirectorJul 28Sale159.122,919,051464,479,3950Jul 29 04:42 PM
BOUSBIB ARISee RemarksJul 22Sale160.0046,0807,372,800652,035Jul 24 05:09 PM
BOUSBIB ARISee RemarksJun 02Sale150.11164,87724,749,686652,035Jun 04 05:35 PM
BOUSBIB ARISee RemarksJun 01Sale150.0019,4432,916,450652,035Jun 03 05:35 PM
EVANISKO MICHAEL JDirectorMar 24Option Exercise21.206,600139,92011,850Mar 26 05:00 PM
Knightly Kevin CSee RemarksFeb 21Sale163.432,191358,0750Feb 25 05:02 PM
Knightly Kevin CSee RemarksFeb 19Sale165.095,688939,0322,191Feb 20 05:03 PM
STAUB W RICHARDSee RemarksFeb 18Option Exercise78.2118,2241,425,29935,953Feb 20 05:05 PM
STAUB W RICHARDSee RemarksFeb 18Sale163.7714,5502,382,85421,403Feb 20 05:05 PM
TPG Group Holdings (SBS) AdvisDirectorFeb 13Sale164.302,996,172492,271,0602,919,051Feb 18 07:00 PM
CONNAUGHTON JOHNDirectorFeb 13Sale164.30703,828115,638,940685,712Feb 18 04:29 PM
EVANISKO MICHAEL JDirectorJan 31Option Exercise23.706,250148,12511,500Feb 04 05:02 PM
EVANISKO MICHAEL JDirectorJan 31Sale155.196,250969,9385,250Feb 04 05:02 PM
EVANISKO MICHAEL JDirectorJan 24Option Exercise20.316,250126,92511,500Jan 28 05:00 PM
EVANISKO MICHAEL JDirectorJan 24Sale159.076,250994,1885,250Jan 28 05:00 PM
EVANISKO MICHAEL JDirectorJan 17Option Exercise18.406,250115,00011,500Jan 21 05:00 PM
EVANISKO MICHAEL JDirectorJan 17Sale160.766,2501,004,7505,250Jan 21 05:00 PM
EVANISKO MICHAEL JDirectorJan 10Option Exercise18.406,250115,00011,500Jan 14 04:56 PM
EVANISKO MICHAEL JDirectorJan 10Sale160.086,2501,000,5005,250Jan 14 04:56 PM
MCDONNELL MICHAEL REVP and CFOJan 02Sale155.0712,0001,860,84014,366Jan 06 05:05 PM
LEONARD JOHN M.DirectorDec 20Option Exercise64.7720,2001,308,25428,452Dec 26 04:33 PM
LEONARD JOHN M.DirectorDec 20Sale153.0020,2003,090,6008,252Dec 26 04:33 PM
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E- EPS (ttm)-1.57 Insider Own0.40% Shs Outstand218.78M Perf Week-0.13%
Market Cap18.13B Forward P/E22.30 EPS next Y3.73 Insider Trans-29.92% Shs Float215.56M Perf Month-8.85%
Income-334.50M PEG- EPS next Q0.75 Inst Own95.00% Short Float2.02% Perf Quarter-8.12%
Sales2.46B P/S7.38 EPS this Y304.40% Inst Trans-1.31% Short Ratio3.65 Perf Half Y-12.10%
Book/sh10.93 P/B7.61 EPS next Y692.10% ROA-10.50% Target Price102.13 Perf Year-11.54%
Cash/sh7.96 P/C10.45 EPS next 5Y25.85% ROE-14.40% 52W Range62.48 - 110.36 Perf YTD-4.79%
Dividend- P/FCF- EPS past 5Y55.60% ROI13.70% 52W High-24.67% Beta0.96
Dividend %- Quick Ratio3.50 Sales past 5Y33.40% Gross Margin95.70% 52W Low33.07% ATR2.70
Employees1456 Current Ratio3.60 Sales Q/Q12.50% Oper. Margin-13.60% RSI (14)47.04 Volatility2.81% 3.13%
OptionableYes Debt/Eq0.02 EPS Q/Q-111.80% Profit Margin-13.60% Rel Volume0.72 Prev Close82.90
ShortableYes LT Debt/Eq0.01 EarningsNov 05 BMO Payout- Avg Volume1.19M Price83.14
Recom2.30 SMA200.46% SMA50-4.45% SMA200-8.67% Volume857,875 Change0.29%
Jun-16-20Initiated The Benchmark Company Hold
May-06-20Downgrade JP Morgan Overweight → Neutral $89 → $99
Apr-29-20Downgrade Morgan Stanley Overweight → Equal-Weight $94
Apr-01-20Upgrade Morgan Stanley Equal-Weight → Overweight $83 → $90
Mar-24-20Resumed William Blair Outperform
Mar-13-20Upgrade BofA/Merrill Neutral → Buy $83
Feb-04-20Resumed BofA/Merrill Neutral $82
Jan-03-20Reiterated BMO Capital Markets Market Perform $85 → $74
Jan-03-20Downgrade Mizuho Buy → Neutral $98 → $79
Jan-02-20Downgrade Guggenheim Buy → Neutral
Oct-03-19Initiated Mizuho Buy $95
Sep-12-19Initiated BMO Capital Markets Market Perform
Sep-05-19Upgrade Oppenheimer Perform → Outperform $100
Sep-05-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $107
Sep-05-19Resumed Morgan Stanley Equal-Weight $82 → $87
May-21-19Initiated Credit Suisse Neutral $75
May-03-19Downgrade Barclays Overweight → Equal Weight $90 → $82
Apr-11-19Initiated Stifel Hold $82
Apr-03-19Downgrade RBC Capital Mkts Outperform → Sector Perform $89
Jan-24-19Upgrade William Blair Mkt Perform → Outperform
Dec-05-20 11:32AM  
Dec-04-20 12:30PM  
Nov-25-20 08:03AM  
Nov-24-20 01:21PM  
Nov-20-20 10:03AM  
Nov-19-20 05:20PM  
Nov-12-20 10:26AM  
08:00AM  
07:44AM  
Nov-11-20 04:02PM  
03:15AM  
Nov-10-20 07:30AM  
Nov-09-20 08:00AM  
Nov-08-20 08:20AM  
Nov-05-20 08:00PM  
04:11PM  
10:12AM  
08:15AM  
07:00AM  
06:15AM  
Nov-04-20 03:55PM  
08:25AM  
Nov-03-20 07:31AM  
Nov-02-20 02:00PM  
Oct-31-20 10:45AM  
05:29AM  
Oct-30-20 09:00AM  
06:45AM  
Oct-29-20 12:35PM  
10:51AM  
08:00AM  
Oct-27-20 04:29PM  
04:25PM  
Oct-20-20 08:00AM  
Oct-08-20 11:39AM  
Oct-05-20 12:48PM  
Sep-18-20 03:48PM  
12:11PM  
07:44AM  
06:00AM  
Sep-17-20 04:31PM  
04:03PM  
Sep-16-20 01:57PM  
Sep-15-20 08:43PM  
Sep-14-20 04:38PM  
04:31PM  
03:15PM  
07:48AM  
06:30AM  
Sep-09-20 10:05AM  
Sep-04-20 06:28PM  
Sep-03-20 11:31AM  
Sep-02-20 05:04PM  
Sep-01-20 08:00AM  
Aug-18-20 04:02PM  
Aug-07-20 09:11AM  
Aug-04-20 04:11PM  
03:00PM  
10:10AM  
09:58AM  
08:45AM  
07:00AM  
Aug-03-20 09:55AM  
08:38AM  
08:21AM  
02:08AM  
Jul-31-20 07:51PM  
Jul-30-20 07:32PM  
Jul-28-20 12:33PM  
11:40AM  
Jul-27-20 01:54PM  
Jul-24-20 02:06PM  
Jul-23-20 07:15AM  
Jul-20-20 12:53PM  
Jul-16-20 08:00AM  
Jul-15-20 01:15PM  
Jul-09-20 02:00PM  
Jul-08-20 02:17PM  
Jun-29-20 07:05AM  
Jun-26-20 10:37AM  
Jun-23-20 10:24AM  
Jun-22-20 12:05PM  
12:05PM  
09:34AM  
08:36AM  
Jun-17-20 08:00AM  
Jun-15-20 03:18PM  
08:40AM  
08:00AM  
07:36AM  
Jun-05-20 12:38PM  
Jun-04-20 10:24PM  
11:31AM  
Jun-03-20 08:00AM  
May-29-20 08:00AM  
May-21-20 08:35AM  
08:00AM  
May-20-20 02:30PM  
02:00PM  
01:18PM  
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naive chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited, as well as a clinical collaboration with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pasquale Maria EEVP & General CounselNov 12Option Exercise65.361278,30128,586Nov 16 04:56 PM
BIENAIME JEAN JACQUESDirectorNov 10Sale83.0079866,2348,646Nov 12 04:41 PM
Dhanak DashyantEVP & Chief Scientific OfficerNov 06Option Exercise65.4296162,86928,971Nov 10 04:26 PM
Dhanak DashyantEVP & Chief Scientific OfficerNov 06Sale85.1796181,84828,010Nov 10 04:26 PM
Flannelly Barry PEVP & General Manager USNov 02Option Exercise48.4420,000968,80059,984Nov 04 04:15 PM
Flannelly Barry PEVP & General Manager USNov 02Sale86.6020,0001,732,00039,984Nov 04 04:15 PM
Pasquale Maria EEVP & General CounselOct 12Option Exercise65.361288,36628,459Oct 13 05:10 PM
Pasquale Maria EEVP & General CounselOct 09Option Exercise68.621,42397,64629,754Oct 13 05:10 PM
Pasquale Maria EEVP & General CounselOct 09Sale95.001,423135,18528,331Oct 13 05:10 PM
Dhanak DashyantEVP & Chief Scientific OfficerOct 06Option Exercise65.4296162,86928,971Oct 08 04:21 PM
Dhanak DashyantEVP & Chief Scientific OfficerOct 06Sale91.9796188,38328,010Oct 08 04:21 PM
Pasquale Maria EEVP & General CounselSep 11Option Exercise65.361278,30128,331Sep 14 04:19 PM
Pasquale Maria EEVP & General CounselSep 10Option Exercise65.362,193143,33430,397Sep 14 04:19 PM
Pasquale Maria EEVP & General CounselSep 10Sale90.832,193199,19028,204Sep 14 04:19 PM
Dhanak DashyantEVP & Chief Scientific OfficerSep 08Option Exercise65.4296162,86928,971Sep 10 04:21 PM
Dhanak DashyantEVP & Chief Scientific OfficerSep 08Sale88.9496185,47128,010Sep 10 04:21 PM
DIXON WENDY LDirectorAug 27Option Exercise18.9720,000379,40034,243Aug 31 04:26 PM
DIXON WENDY LDirectorAug 27Sale94.5120,0001,890,20014,243Aug 31 04:26 PM
Pasquale Maria EEVP & General CounselAug 10Option Exercise65.361288,36628,204Aug 12 04:08 PM
Dhanak DashyantEVP & Chief Scientific OfficerAug 06Option Exercise65.4296162,86928,971Aug 10 04:20 PM
Dhanak DashyantEVP & Chief Scientific OfficerAug 06Sale97.8096193,98628,010Aug 10 04:20 PM
Stein Steven HEVP & Chief Medical OfficerJul 16Sale103.8376679,53495,468Jul 17 04:20 PM
Dhanak DashyantEVP & Chief Scientific OfficerJul 13Option Exercise65.422,419158,25128,010Jul 14 04:31 PM
Pasquale Maria EEVP & General CounselJul 10Option Exercise65.361278,30128,076Jul 14 04:39 PM
Stein Steven HEVP & Chief Medical OfficerJul 08Sale108.5661066,22296,857Jul 08 05:27 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJul 08Sale108.5647551,56625,926Jul 08 05:31 PM
Hoppenot HerveChairman / CEOJul 07Option Exercise73.2189,7716,572,135354,907Jul 07 07:18 PM
Stein Steven HEVP & Chief Medical OfficerJul 07Option Exercise88.6810,876964,484108,245Jul 08 05:27 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJul 07Sale107.983,120336,89826,401Jul 08 05:31 PM
Stein Steven HEVP & Chief Medical OfficerJul 07Sale109.5614,1591,551,32697,467Jul 08 05:27 PM
Hoppenot HerveChairman / CEOJul 07Sale110.0089,7719,874,810266,501Jul 07 07:18 PM
Wenqing YaoEVP, Head of Discovery ChemJul 06Option Exercise64.5516,5531,068,496171,906Jul 07 07:30 PM
Stein Steven HEVP & Chief Medical OfficerJul 06Option Exercise75.5233,6022,537,457112,882Jul 07 07:25 PM
Dhanak DashyantEVP & Chief Scientific OfficerJul 06Option Exercise65.4296162,86926,552Jul 07 07:13 PM
Dhanak DashyantEVP & Chief Scientific OfficerJul 06Sale106.58961102,42325,591Jul 07 07:13 PM
Stein Steven HEVP & Chief Medical OfficerJul 06Sale107.2536,1243,874,171100,750Jul 07 07:25 PM
Wenqing YaoEVP, Head of Discovery ChemJul 06Sale107.3216,5531,776,468156,258Jul 07 07:30 PM
Hoppenot HerveChairman / CEOJun 26Option Exercise64.55124,1488,013,753360,104Jun 30 04:06 PM
Hoppenot HerveChairman / CEOJun 26Sale102.91124,14812,776,071240,603Jun 30 04:06 PM
Flannelly Barry PEVP & General Manager USJun 23Option Exercise73.2159943,85336,461Jun 25 05:09 PM
Trower PaulPrincipal Accounting OfficerJun 23Option Exercise64.556,943448,17128,677Jun 25 05:15 PM
Flannelly Barry PEVP & General Manager USJun 23Sale110.0040044,00036,061Jun 25 05:09 PM
Trower PaulPrincipal Accounting OfficerJun 23Sale110.006,943763,73021,734Jun 25 05:15 PM
Dickinson Jonathan ElliottEVP, General Manager, EuropeJun 22Sale105.319,000947,79021,762Jun 23 04:17 PM
Pasquale Maria EEVP & General CounselJun 19Option Exercise72.271,423102,84025,084Jun 23 04:42 PM
Flannelly Barry PEVP & General Manager USJun 19Option Exercise73.217,181525,72143,043Jun 23 04:23 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJun 19Option Exercise72.867,866573,11732,767Jun 23 04:33 PM
Flannelly Barry PEVP & General Manager USJun 19Sale105.007,181754,00535,862Jun 23 04:23 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJun 19Sale105.007,866825,93024,901Jun 23 04:33 PM
Pasquale Maria EEVP & General CounselJun 19Sale100.001,423142,30023,661Jun 23 04:42 PM
Pasquale Maria EEVP & General CounselJun 12Option Exercise65.361278,30123,661Jun 16 04:24 PM
Pasquale Maria EEVP & General CounselJun 10Option Exercise66.643,615240,91525,726Jun 12 04:11 PM
Pasquale Maria EEVP & General CounselJun 10Sale94.513,615341,64923,534Jun 12 04:11 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 08Option Exercise65.4296162,86920,948Jun 10 04:34 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 08Sale91.8796188,28719,987Jun 10 04:34 PM
BAKER BROS. ADVISORS LPDirectorMay 28Buy102.55220529,313,198May 28 08:07 PM
Pasquale Maria EEVP & General CounselMay 11Option Exercise65.361288,36623,534May 13 04:38 PM
Dhanak DashyantEVP & Chief Scientific OfficerMay 06Option Exercise65.4296162,86920,948May 08 04:53 PM
Dhanak DashyantEVP & Chief Scientific OfficerMay 06Sale96.8496193,06319,987May 08 04:53 PM
BAKER BROS. ADVISORS LPDirectorApr 28Option Exercise13.3440,000533,60029,311,915Apr 29 04:45 PM
Trower PaulPrincipal Accounting OfficerApr 17Option Exercise64.551,14373,78122,467Apr 21 04:35 PM
Pasquale Maria EEVP & General CounselApr 17Option Exercise72.279,488685,69832,837Apr 20 05:08 PM
Flannelly Barry PEVP & General Manager USApr 17Option Exercise73.216,583481,94141,925Apr 21 04:28 PM
Pasquale Maria EEVP & General CounselApr 17Sale100.009,488948,80022,899Apr 20 05:08 PM
Trower PaulPrincipal Accounting OfficerApr 17Sale100.001,143114,30021,324Apr 21 04:35 PM
Flannelly Barry PEVP & General Manager USApr 17Sale100.006,583658,30035,342Apr 21 04:28 PM
Pasquale Maria EEVP & General CounselApr 16Option Exercise68.629,488651,06732,837Apr 20 05:08 PM
Pasquale Maria EEVP & General CounselApr 16Sale95.009,488901,36022,899Apr 20 05:08 PM
Pasquale Maria EEVP & General CounselApr 14Option Exercise65.3617,8271,165,17340,726Apr 15 04:57 PM
Pasquale Maria EEVP & General CounselApr 14Sale90.0017,8271,604,43022,899Apr 15 04:57 PM
Pasquale Maria EEVP & General CounselApr 13Option Exercise65.361278,30123,864Apr 15 04:57 PM
Pasquale Maria EEVP & General CounselApr 13Sale85.6896582,68122,899Apr 15 04:57 PM
Dhanak DashyantEVP & Chief Scientific OfficerApr 06Option Exercise65.423,844251,47423,831Apr 08 04:35 PM
Pasquale Maria EEVP & General CounselApr 06Sale85.001,842156,57024,254Apr 08 04:39 PM
Dhanak DashyantEVP & Chief Scientific OfficerApr 06Sale85.003,844326,74019,987Apr 08 04:35 PM
SWAIN PAULA JEVP, Human ResourcesMar 31Option Exercise64.552,329150,33750,132Apr 02 05:32 PM
SWAIN PAULA JEVP, Human ResourcesMar 31Sale71.442,329166,38448,493Apr 02 05:32 PM
Pasquale Maria EEVP & General CounselMar 11Option Exercise65.361288,36626,096Mar 13 04:18 PM
BROOKE PAUL ADirectorFeb 21Option Exercise13.3420,000266,800221,584Feb 25 04:39 PM
SWAIN PAULA JEVP, Human ResourcesFeb 19Option Exercise64.552,500161,37550,993Feb 21 04:11 PM
SWAIN PAULA JEVP, Human ResourcesFeb 19Sale80.002,500200,00048,493Feb 21 04:11 PM
Pasquale Maria EEVP & General CounselFeb 10Option Exercise65.361278,30119,087Feb 12 05:00 PM
Wenqing YaoEVP, Head of Discovery ChemFeb 05Option Exercise18.3217,542321,369112,850Feb 07 04:48 PM
Wenqing YaoEVP, Head of Discovery ChemFeb 05Sale75.9717,5421,332,66695,308Feb 07 04:48 PM
SWAIN PAULA JEVP, Human ResourcesJan 15Option Exercise64.552,500161,37544,112Jan 17 04:20 PM
SWAIN PAULA JEVP, Human ResourcesJan 15Sale81.122,500202,80041,612Jan 17 04:20 PM
Pasquale Maria EEVP & General CounselJan 10Option Exercise65.361278,30118,960Jan 14 04:54 PM
SWAIN PAULA JEVP, Human ResourcesDec 16Option Exercise64.552,500161,37544,112Dec 18 04:59 PM
SWAIN PAULA JEVP, Human ResourcesDec 16Sale91.612,500229,02541,612Dec 18 04:59 PM
Pasquale Maria EEVP & General CounselDec 12Option Exercise65.36775,03318,833Dec 16 04:35 PM
PGEN Precigen, Inc. daily Stock Chart
PGEN [NASD]
Precigen, Inc.
Index- P/E- EPS (ttm)-0.97 Insider Own1.00% Shs Outstand165.53M Perf Week13.08%
Market Cap1.57B Forward P/E- EPS next Y-0.53 Insider Trans426.15% Shs Float151.49M Perf Month62.26%
Income-155.90M PEG- EPS next Q-0.14 Inst Own67.40% Short Float17.86% Perf Quarter66.73%
Sales92.20M P/S17.05 EPS this Y57.60% Inst Trans1.10% Short Ratio24.30 Perf Half Y127.69%
Book/sh0.35 P/B24.20 EPS next Y39.80% ROA-76.50% Target Price9.00 Perf Year58.02%
Cash/sh0.61 P/C13.90 EPS next 5Y2.40% ROE-446.50% 52W Range1.26 - 9.15 Perf YTD54.56%
Dividend- P/FCF- EPS past 5Y-10.10% ROI-69.70% 52W High-7.43% Beta2.26
Dividend %- Quick Ratio4.60 Sales past 5Y4.80% Gross Margin39.80% 52W Low572.22% ATR0.63
Employees770 Current Ratio4.90 Sales Q/Q29.00% Oper. Margin- RSI (14)76.44 Volatility9.51% 9.18%
OptionableYes Debt/Eq3.31 EPS Q/Q43.80% Profit Margin- Rel Volume1.04 Prev Close8.48
ShortableYes LT Debt/Eq3.31 EarningsNov 09 AMC Payout- Avg Volume1.11M Price8.47
Recom2.30 SMA2029.83% SMA5062.93% SMA200100.33% Volume1,155,734 Change-0.06%
May-08-20Initiated H.C. Wainwright Buy $5
Dec-04-20 11:30AM  
11:00AM  
09:37AM  
09:05AM  
08:00AM  
Dec-03-20 11:58PM  
05:29PM  
04:54PM  
01:20PM  
01:00PM  
10:40AM  
09:30AM  
04:25AM  
01:00AM  
Dec-02-20 02:30PM  
02:12PM  
11:00AM  
11:00AM  
09:37AM  
Dec-01-20 11:59PM  
02:42PM  
11:00AM  
09:18AM  
Nov-30-20 08:00PM  
04:31PM  
01:00PM  
11:00AM  
09:20AM  
Nov-29-20 03:21PM  
01:00PM  
Nov-28-20 01:16PM  
09:39AM  
09:00AM  
Nov-27-20 05:00PM  
03:57PM  
10:28AM  
10:11AM  
Nov-26-20 01:30PM  
Nov-25-20 04:38PM  
12:52PM  
12:45PM  
12:40PM  
11:00AM  
Nov-24-20 06:00PM  
01:46PM  
01:00PM  
11:00AM  
10:19AM  
09:16AM  
Nov-23-20 11:15PM  
05:04PM  
03:12PM  
12:00PM  
11:00AM  
Nov-22-20 12:24AM  
Nov-20-20 05:42PM  
Nov-19-20 03:55PM  
10:58AM  
Nov-18-20 10:00PM  
05:00PM  
03:52PM  
12:19PM  
12:15PM  
Nov-17-20 05:06PM  
04:04PM  
12:30PM  
11:00AM  
09:39AM  
Nov-16-20 09:51PM  
04:50PM  
11:30AM  
08:05AM  
Nov-14-20 04:15PM  
Nov-13-20 07:04PM  
04:10PM  
12:00PM  
Nov-12-20 08:05PM  
03:22PM  
02:45PM  
09:47AM  
08:00AM  
Nov-11-20 05:00PM  
03:20PM  
01:25PM  
11:00AM  
Nov-10-20 03:05PM  
12:30PM  
11:00AM  
Nov-09-20 11:15PM  
04:08PM  
04:05PM  
12:00PM  
08:05AM  
Nov-08-20 03:03AM  
Nov-06-20 07:23PM  
04:29PM  
11:30AM  
Nov-05-20 03:50PM  
01:19PM  
Nov-04-20 06:10PM  
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ares Trading S.A.10% OwnerOct 07Buy3.706,758,40024,999,99727,398,519Oct 09 08:09 AM
Sterling Rick L.Chief Financial OfficerSep 16Sale5.227,66039,985305,313Sep 17 06:39 PM
Perez Jeffrey ThomasSVP, IP AffairsSep 16Sale5.227,66039,985243,229Sep 17 06:35 PM
Lehr Donald P.Chief Legal OfficerSep 16Sale5.228,47444,234248,084Sep 17 06:29 PM
KIRK RANDAL JExecutive ChairmanAug 12Buy4.26400,8661,707,68913,495,622Aug 13 04:24 PM
KIRK RANDAL JExecutive ChairmanAug 11Buy4.50808,5183,638,33113,216,701Aug 13 04:24 PM
Sabzevari HelenPresident and CEOJul 20Sale4.5812,22055,968402,145Jul 21 06:40 PM
Frank StevenDirectorJun 30Option Exercise3.172,9689,409265,563Jul 06 04:22 PM
ALVAREZ CESAR LDirectorJun 23Option Exercise3.172,9689,409184,133Jun 25 04:22 PM
MITCHELL DEAN JDirectorJun 19Option Exercise3.172,9689,409105,441Jun 23 04:57 PM
Lehr Donald P.Chief Legal OfficerJun 16Sale4.508,42837,926231,558Jun 17 04:35 PM
Perez Jeffrey ThomasSVP, IP AffairsJun 16Sale4.507,61934,286225,889Jun 17 04:32 PM
Sterling Rick L.Chief Financial OfficerJun 16Sale4.507,61934,286287,973Jun 17 04:32 PM
Lehr Donald P.Chief Legal OfficerMay 18Sale2.3662,895148,659214,986May 19 04:33 PM
Sterling Rick L.Chief Financial OfficerMay 18Sale2.3656,853134,372270,592May 19 04:34 PM
Perez Jeffrey ThomasSVP, IP AffairsMay 18Sale2.3656,853134,372208,508May 19 04:33 PM
Sabzevari HelenPresident and CEOMay 15Sale2.37217,527515,800389,365May 18 04:04 PM
EXAS Exact Sciences Corporation daily Stock Chart
EXAS [NASD]
Exact Sciences Corporation
Index- P/E- EPS (ttm)-2.20 Insider Own0.70% Shs Outstand150.16M Perf Week12.42%
Market Cap20.78B Forward P/E- EPS next Y-1.34 Insider Trans-19.18% Shs Float- Perf Month7.89%
Income-333.80M PEG- EPS next Q-0.30 Inst Own89.10% Short Float- Perf Quarter77.87%
Sales1.32B P/S15.73 EPS this Y55.40% Inst Trans3.85% Short Ratio5.52 Perf Half Y46.80%
Book/sh15.56 P/B8.54 EPS next Y54.00% ROA-8.00% Target Price150.43 Perf Year58.92%
Cash/sh8.20 P/C16.20 EPS next 5Y- ROE-13.80% 52W Range35.25 - 141.90 Perf YTD43.67%
Dividend- P/FCF- EPS past 5Y12.50% ROI-1.90% 52W High-6.36% Beta1.65
Dividend %- Quick Ratio6.00 Sales past 5Y244.80% Gross Margin75.50% 52W Low276.92% ATR6.27
Employees4110 Current Ratio6.40 Sales Q/Q86.70% Oper. Margin-33.40% RSI (14)65.82 Volatility4.85% 4.18%
OptionableYes Debt/Eq0.68 EPS Q/Q-368.20% Profit Margin-25.30% Rel Volume1.10 Prev Close130.67
ShortableYes LT Debt/Eq0.68 EarningsOct 29 AMC Payout- Avg Volume2.13M Price132.87
Recom1.50 SMA2010.26% SMA5016.92% SMA20051.44% Volume2,347,773 Change1.68%
Oct-29-20Downgrade UBS Buy → Neutral $125 → $140
Oct-28-20Downgrade Citigroup Buy → Neutral $120 → $140
Oct-08-20Resumed BTIG Research Buy $140
Apr-02-20Initiated Evercore ISI Outperform $70
Jan-10-20Resumed BTIG Research Buy $127
Jan-07-20Initiated Citigroup Buy $120
Dec-13-19Initiated Dougherty & Company Buy $120
Nov-15-19Initiated Stifel Buy
Oct-17-19Reiterated BofA/Merrill Buy $130 → $135
Oct-01-19Resumed Craig Hallum Buy $127
Sep-26-19Initiated Oppenheimer Outperform $130
Feb-26-19Upgrade Goldman Neutral → Buy $85 → $120
Oct-09-18Initiated UBS Buy
Sep-05-18Resumed The Benchmark Company Hold
Aug-13-18Reiterated Canaccord Genuity Buy $62 → $65
Apr-03-18Upgrade BTIG Research Neutral → Buy
Jan-29-18Initiated Goldman Neutral $51
Jan-08-18Reiterated The Benchmark Company Buy $60 → $65
Nov-13-17Downgrade Robert W. Baird Outperform → Neutral $56
Nov-01-17Downgrade BTIG Research Buy → Neutral
Dec-03-20 06:30AM  
Nov-23-20 06:00AM  
Nov-14-20 12:05PM  
08:08AM  
Nov-13-20 11:11AM  
08:30AM  
Nov-08-20 09:06PM  
Nov-02-20 10:45AM  
06:00AM  
Oct-28-20 12:16PM  
10:24AM  
07:41AM  
Oct-27-20 04:35PM  
03:03PM  
02:09PM  
12:44PM  
11:26AM  
10:29AM  
10:25AM  
09:55AM  
08:19AM  
07:54AM  
07:14AM  
07:10AM  
07:01AM  
07:00AM  
Oct-26-20 09:01PM  
Oct-22-20 12:34PM  
Oct-12-20 09:00AM  
Oct-10-20 03:00PM  
Oct-09-20 06:00AM  
Oct-08-20 09:00AM  
Oct-07-20 06:11AM  
Oct-04-20 06:27AM  
Oct-01-20 02:22PM  
Sep-29-20 07:27AM  
Sep-28-20 08:53AM  
Sep-25-20 09:22AM  
Sep-24-20 03:37PM  
02:47PM  
02:35PM  
12:11PM  
Sep-21-20 04:27PM  
11:25AM  
Sep-17-20 06:00AM  
Sep-07-20 12:52PM  
Sep-01-20 04:05PM  
Aug-29-20 11:31AM  
Aug-01-20 04:03AM  
Jul-31-20 12:13PM  
11:13AM  
06:38AM  
Jul-30-20 06:30PM  
Jul-29-20 08:40AM  
Jul-23-20 12:32PM  
11:30AM  
Jul-17-20 08:00AM  
Jul-12-20 12:00PM  
Jul-08-20 07:45AM  
06:00AM  
Jun-16-20 03:09PM  
08:00AM  
Jun-05-20 11:31AM  
Jun-03-20 09:49AM  
01:15AM  
May-29-20 08:00AM  
May-26-20 06:00AM  
May-17-20 06:46AM  
May-12-20 03:10PM  
10:23AM  
May-11-20 10:19AM  
May-07-20 11:30AM  
10:09AM  
May-06-20 08:05PM  
03:00PM  
May-05-20 10:30AM  
10:16AM  
10:06AM  
08:45AM  
May-04-20 06:00AM  
May-03-20 07:36AM  
Apr-30-20 10:49AM  
Apr-29-20 12:34PM  
Apr-22-20 05:20AM  
Apr-08-20 05:51PM  
06:00AM  
Apr-02-20 09:00AM  
06:00AM  
Mar-26-20 05:45PM  
01:50PM  
Mar-24-20 09:44AM  
Mar-21-20 09:22AM  
Mar-19-20 06:00AM  
Mar-17-20 05:45PM  
03:18PM  
Mar-12-20 11:30AM  
Mar-04-20 07:37AM  
Feb-27-20 08:42AM  
Feb-25-20 08:28AM  
Feb-24-20 10:39PM  
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Conroy Kevin TPresident and CEODec 01Sale124.5630,5773,808,660857,518Dec 02 06:28 PM
Conroy Kevin TPresident and CEONov 02Sale121.1132,8193,974,738888,095Nov 03 04:49 PM
Conroy Kevin TPresident and CEOOct 01Sale103.5527,4252,839,829920,914Oct 02 05:54 PM
Hoof TorstenGeneral Manager, InternationalSep 24Option Exercise41.534,401182,7746,418Sep 28 04:33 PM
Hoof TorstenGeneral Manager, InternationalSep 24Sale80.004,401352,0802,017Sep 28 04:33 PM
Conroy Kevin TPresident and CEOSep 01Sale75.0319,9271,495,123948,339Sep 02 04:32 PM
Hoof TorstenGeneral Manager, InternationalAug 19Option Exercise43.401,51665,7949,981Aug 21 04:31 PM
Hoof TorstenGeneral Manager, InternationalAug 19Sale84.907,964676,1442,017Aug 21 04:31 PM
Hoof TorstenGeneral Manager, InternationalAug 17Option Exercise0.002,55108,465Aug 19 04:15 PM
Conroy Kevin TPresident and CEOAug 03Sale93.8025,1982,363,560968,266Aug 04 05:18 PM
Zanotti Katherine SDirectorJul 31Option Exercise8.5221,029179,16762,936Aug 04 04:54 PM
LEVANGIE DANIEL JDirectorJul 31Option Exercise9.309,86591,69924,881Aug 04 04:58 PM
Elliott Jeffrey ThomasChief Financial OfficerJul 31Option Exercise21.686,638143,91275,861Aug 04 05:02 PM
Carey Thomas D.DirectorJul 31Option Exercise9.2415,620144,32952,492Aug 04 05:21 PM
Carey Thomas D.DirectorJul 31Sale94.0030,6202,878,28021,872Aug 04 05:21 PM
Elliott Jeffrey ThomasChief Financial OfficerJul 31Sale93.8337,5003,518,77138,361Aug 04 05:02 PM
LEVANGIE DANIEL JDirectorJul 31Sale94.009,865927,31015,016Aug 04 04:58 PM
Zanotti Katherine SDirectorJul 31Sale94.0021,0291,976,72641,907Aug 04 04:54 PM
Doyle James EdwardDirectorJul 31Sale94.002,539238,66632,459Aug 04 04:45 PM
Elliott Jeffrey ThomasChief Financial OfficerJul 29Sale95.588,746835,94369,223Jul 30 08:18 PM
Elliott Jeffrey ThomasChief Financial OfficerJul 28Option Exercise94.8118,7501,777,68877,969Jul 30 08:18 PM
Zanotti Katherine SDirectorJul 28Sale96.131,164111,89541,907Jul 30 06:49 PM
Stenhouse MarkPresident, CologuardApr 03Sale56.6911,948677,33229,571Apr 06 04:41 PM
Stenhouse MarkPresident, CologuardApr 02Option Exercise0.0025,000041,519Apr 06 04:41 PM
Doyle James EdwardDirectorFeb 28Sale77.542,000155,08032,440Mar 03 07:20 PM
Conroy Kevin TPresident and CEOFeb 28Sale80.179,750781,658992,963Mar 02 07:13 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 28Sale80.172,383191,04558,578Mar 02 07:15 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 27Option Exercise0.005,025061,141Mar 02 07:15 PM
Conroy Kevin TPresident and CEOFeb 27Option Exercise0.0020,57501,002,713Mar 02 07:13 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 27Sale80.271,627130,59956,116Feb 28 04:37 PM
Stenhouse MarkPresident, CologuardFeb 27Sale80.271,05184,36416,519Feb 28 04:39 PM
Conroy Kevin TPresident and CEOFeb 27Sale80.2713,8751,113,746982,138Feb 28 04:36 PM
Conroy Kevin TPresident and CEOFeb 26Option Exercise0.0029,3370996,013Feb 28 04:36 PM
Stenhouse MarkPresident, CologuardFeb 26Option Exercise0.003,262017,570Feb 28 04:39 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 26Option Exercise0.003,436057,743Feb 28 04:37 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 25Sale85.114,910417,89054,307Feb 26 05:13 PM
Conroy Kevin TPresident and CEOFeb 25Sale85.1118,1151,541,768966,676Feb 26 05:11 PM
Conroy Kevin TPresident and CEOFeb 24Option Exercise0.0034,3250984,791Feb 26 05:11 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 24Option Exercise0.009,300059,217Feb 26 05:13 PM
Cole G BradleyGeneral Manager - DiagnosticsFeb 19Option Exercise35.7717,356620,77637,550Feb 21 04:58 PM
Cole G BradleyGeneral Manager - DiagnosticsFeb 19Sale100.0027,3562,735,60010,194Feb 21 04:58 PM
ORVILLE JACOB AGeneral Manager, New VenturesFeb 19Sale100.681,153116,0842,495Feb 20 05:55 PM
ORVILLE JACOB AGeneral Manager, New VenturesFeb 18Option Exercise0.003,64803,648Feb 20 05:55 PM
Hoof TorstenGeneral Manager, InternationalFeb 15Option Exercise0.002,09105,914Mar 27 04:15 PM
Cole G BradleyGeneral Manager - DiagnosticsJan 16Sale90.3010,000903,0008,653Jan 17 04:50 PM
Conroy Kevin TPresident and CEODec 16Option Exercise17.4811,440199,992950,466Dec 18 05:19 PM
PPD PPD, Inc. daily Stock Chart
PPD [NASD]
PPD, Inc.
Index- P/E226.30 EPS (ttm)0.15 Insider Own0.30% Shs Outstand348.58M Perf Week-0.63%
Market Cap12.03B Forward P/E25.18 EPS next Y1.38 Insider Trans-98.31% Shs Float214.38M Perf Month-0.49%
Income53.80M PEG16.76 EPS next Q0.36 Inst Own62.20% Short Float1.24% Perf Quarter8.00%
Sales4.36B P/S2.76 EPS this Y-43.50% Inst Trans16.02% Short Ratio1.49 Perf Half Y29.94%
Book/sh-3.06 P/B- EPS next Y19.00% ROA1.10% Target Price39.87 Perf Year-
Cash/sh2.01 P/C17.36 EPS next 5Y13.50% ROE-3.40% 52W Range10.61 - 37.51 Perf YTD16.17%
Dividend- P/FCF40.80 EPS past 5Y- ROI14.10% 52W High-7.09% Beta-
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin39.50% 52W Low228.46% ATR1.28
Employees23000 Current Ratio1.10 Sales Q/Q1.40% Oper. Margin8.50% RSI (14)51.89 Volatility3.22% 3.61%
OptionableYes Debt/Eq- EPS Q/Q-140.80% Profit Margin1.50% Rel Volume0.46 Prev Close34.40
ShortableYes LT Debt/Eq- EarningsOct 28 BMO Payout0.00% Avg Volume1.79M Price34.85
Recom1.70 SMA201.32% SMA50-0.32% SMA20019.85% Volume825,044 Change1.31%
Oct-12-20Initiated Truist Buy
Jun-04-20Initiated KeyBanc Capital Markets Overweight $35
Mar-23-20Upgrade Jefferies Hold → Buy $30.50 → $20
Mar-02-20Initiated William Blair Outperform
Mar-02-20Initiated UBS Buy $34
Mar-02-20Initiated Robert W. Baird Outperform $35
Mar-02-20Initiated Morgan Stanley Overweight $34
Mar-02-20Initiated Mizuho Buy $32
Mar-02-20Initiated JP Morgan Overweight $35
Mar-02-20Initiated Jefferies Hold $30.50
Mar-02-20Initiated Goldman Buy $34
Mar-02-20Initiated Evercore ISI Outperform $33
Mar-02-20Initiated Deutsche Bank Buy $33
Mar-02-20Initiated Credit Suisse Outperform $32
Mar-02-20Initiated Citigroup Buy $34
Mar-02-20Initiated BofA/Merrill Buy $33
Mar-02-20Initiated Barclays Overweight $33
Nov-02-20 10:15AM  
Oct-29-20 10:36AM  
Oct-28-20 07:00AM  
Oct-27-20 04:05PM  
Oct-26-20 08:00AM  
Oct-13-20 09:00AM  
Oct-12-20 04:05PM  
01:39PM  
Oct-06-20 09:00AM  
Sep-30-20 09:00AM  
Sep-28-20 01:24PM  
Sep-17-20 12:00PM  
Sep-16-20 10:32PM  
Sep-14-20 04:06PM  
04:05PM  
Sep-09-20 09:00AM  
Sep-03-20 09:00AM  
Aug-24-20 11:05AM  
Aug-20-20 07:55AM  
Aug-14-20 09:00AM  
Aug-12-20 03:11PM  
Aug-04-20 04:05PM  
Aug-03-20 09:00AM  
Jul-21-20 04:05PM  
Jul-17-20 12:00PM  
Jun-25-20 09:00AM  
Jun-04-20 09:42AM  
May-21-20 05:20PM  
07:10AM  
May-14-20 09:00AM  
May-06-20 04:01PM  
09:42AM  
May-01-20 04:55PM  
Apr-29-20 09:05AM  
Apr-23-20 09:00AM  
Apr-16-20 09:00AM  
Apr-02-20 09:00AM  
Mar-17-20 09:00AM  
Mar-10-20 04:01PM  
Mar-05-20 04:01PM  
Mar-04-20 04:01PM  
Mar-03-20 10:03AM  
Mar-02-20 02:31PM  
Feb-25-20 09:15AM  
Feb-20-20 09:00AM  
Feb-17-20 10:36AM  
Feb-16-20 04:07PM  
Feb-07-20 04:17PM  
Feb-06-20 04:33PM  
11:15AM  
Feb-05-20 07:44PM  
06:08PM  
06:00PM  
Feb-01-20 02:34PM  
Jan-27-20 07:31AM  
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIMMONS DAVID SChief Executive OfficerNov 10Option Exercise10.5930,000317,700987,759Nov 12 04:02 PM
SIMMONS DAVID SChief Executive OfficerOct 30Option Exercise10.5950,000529,500957,759Nov 03 04:43 PM
HARTMAN JUDDSee RemarksSep 29Sale34.6030,0001,038,00064,166Oct 01 05:00 PM
Kaucic KarenSee RemarksSep 29Sale34.8020,574715,9758,392Oct 01 05:00 PM
Pellegrino JillSVP & General Manager of AESSep 28Option Exercise15.052,83742,6975,495Sep 30 05:00 PM
Pellegrino JillSVP & General Manager of AESSep 28Sale34.405,495189,0280Sep 30 05:00 PM
Donovan GlenChief Accounting OfficerSep 22Sale34.762,83398,4753,000Sep 24 05:00 PM
Johnston David MichaelSee RemarksSep 21Sale33.1140,0001,324,40053,107Sep 23 05:01 PM
H&F Corporate Investors VIII, 10% OwnerSep 21Sale31.2824,702,175772,745,789157,138Sep 23 04:48 PM
H&F Corporate Investors VII, L10% OwnerSep 21Sale31.2824,702,175772,745,789157,138Sep 23 04:47 PM
Hill ColinDirectorSep 21Sale31.281,72253,86814,166Sep 23 04:44 PM
Carlyle Group Management L.L.C10% OwnerSep 21Sale31.2810,732,261335,731,95555,722,733Sep 22 04:15 PM
Garrow Ronald ESee RemarksSep 18Option Exercise14.559,500138,2259,500Sep 22 05:01 PM
Garrow Ronald ESee RemarksSep 18Sale34.129,500324,1400Sep 22 05:01 PM
SYNH Syneos Health, Inc. daily Stock Chart
SYNH [NASD]
Syneos Health, Inc.
Index- P/E35.55 EPS (ttm)1.82 Insider Own0.40% Shs Outstand104.28M Perf Week-2.94%
Market Cap6.51B Forward P/E15.61 EPS next Y4.15 Insider Trans-98.91% Shs Float61.25M Perf Month6.61%
Income192.00M PEG3.45 EPS next Q1.11 Inst Own- Short Float9.26% Perf Quarter9.72%
Sales4.49B P/S1.45 EPS this Y467.60% Inst Trans-0.84% Short Ratio6.88 Perf Half Y11.34%
Book/sh29.69 P/B2.18 EPS next Y21.77% ROA2.60% Target Price75.25 Perf Year19.44%
Cash/sh2.47 P/C26.16 EPS next 5Y10.30% ROE6.30% 52W Range30.02 - 74.25 Perf YTD8.79%
Dividend- P/FCF15.51 EPS past 5Y34.80% ROI4.90% 52W High-12.86% Beta1.86
Dividend %- Quick Ratio1.10 Sales past 5Y31.70% Gross Margin22.50% 52W Low115.52% ATR2.82
Employees24000 Current Ratio1.10 Sales Q/Q-6.60% Oper. Margin6.30% RSI (14)56.59 Volatility3.54% 3.99%
OptionableYes Debt/Eq0.83 EPS Q/Q7.10% Profit Margin4.30% Rel Volume1.19 Prev Close62.62
ShortableYes LT Debt/Eq0.81 EarningsOct 29 BMO Payout0.00% Avg Volume824.55K Price64.70
Recom1.80 SMA201.67% SMA508.49% SMA20013.48% Volume983,070 Change3.32%
Oct-06-20Upgrade Mizuho Neutral → Buy $65
Oct-01-20Upgrade Goldman Neutral → Buy $69 → $75
Mar-30-20Downgrade Goldman Buy → Neutral $79 → $45
Jan-07-20Initiated Citigroup Buy $75
Oct-19-18Upgrade William Blair Mkt Perform → Outperform
Oct-09-18Initiated UBS Buy
Oct-04-18Initiated Evercore ISI Outperform $58
Dec-03-20 08:49AM  
Dec-02-20 08:30AM  
Dec-01-20 04:21PM  
Nov-30-20 11:42AM  
Nov-25-20 03:36AM  
Nov-24-20 06:07PM  
Nov-18-20 06:52PM  
07:22AM  
Nov-17-20 08:40AM  
Nov-16-20 08:43AM  
Nov-13-20 08:15AM  
Nov-12-20 08:56AM  
07:30AM  
Nov-03-20 08:19AM  
Nov-02-20 05:20PM  
10:43AM  
Oct-30-20 01:08PM  
Oct-29-20 07:59AM  
07:35AM  
06:13AM  
06:00AM  
Oct-28-20 05:39PM  
Oct-22-20 12:33PM  
Oct-21-20 06:30AM  
Oct-19-20 06:30AM  
Oct-13-20 08:45AM  
Oct-07-20 11:45AM  
Oct-05-20 04:58PM  
Sep-28-20 09:59AM  
Sep-16-20 06:20PM  
04:52PM  
08:52AM  
Sep-15-20 04:51PM  
Sep-10-20 02:42PM  
Sep-09-20 10:55AM  
Sep-05-20 11:32AM  
Sep-02-20 07:30AM  
Sep-01-20 08:12AM  
Aug-11-20 09:50AM  
Aug-06-20 09:45AM  
06:14AM  
Jul-30-20 12:33PM  
Jul-20-20 11:02AM  
Jul-13-20 08:30AM  
Jul-11-20 05:42PM  
03:46PM  
Jul-07-20 08:00AM  
Jul-01-20 03:37PM  
Jun-22-20 08:42AM  
Jun-19-20 09:38AM  
Jun-17-20 01:52PM  
11:08AM  
Jun-16-20 08:43AM  
08:39AM  
May-30-20 11:31AM  
May-28-20 08:30AM  
May-22-20 08:39AM  
May-13-20 12:15PM  
May-04-20 10:26AM  
Apr-30-20 06:00PM  
07:55AM  
06:34AM  
Apr-23-20 12:32PM  
Apr-07-20 06:54AM  
Apr-03-20 04:17PM  
Apr-02-20 02:54PM  
Apr-01-20 02:31PM  
Mar-30-20 12:09PM  
Mar-27-20 05:13PM  
10:28AM  
Mar-25-20 07:09AM  
Mar-21-20 11:30AM  
Mar-17-20 09:27AM  
Mar-05-20 04:05PM  
Feb-28-20 08:41AM  
08:07AM  
Feb-25-20 01:59PM  
Feb-24-20 02:59PM  
Feb-21-20 07:46AM  
06:43AM  
Feb-20-20 02:46PM  
07:55AM  
06:20AM  
06:00AM  
Feb-19-20 06:56AM  
Feb-13-20 12:31PM  
Jan-22-20 09:00AM  
Jan-20-20 12:59PM  
Jan-09-20 07:00AM  
Jan-08-20 08:01AM  
Jan-03-20 06:00PM  
Dec-30-19 09:31AM  
Dec-11-19 03:56PM  
Dec-09-19 09:15AM  
08:42AM  
Dec-02-19 09:30AM  
Nov-21-19 09:02AM  
Nov-20-19 09:10AM  
Nov-13-19 03:39PM  
08:00AM  
Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including medication adherence, communications solutions, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a strategic agreement with Daiichi Sankyo, Inc. for the development of Daiichi Sankyo'S Adc oncology pipeline. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Meggs Jason M.Chief Financial OfficerNov 27Sale67.004,062272,15466,003Nov 30 05:12 PM
Meggs Jason M.Chief Financial OfficerNov 24Sale67.001,938129,84670,065Nov 25 05:01 PM
KEEFE MICHELLEPres., Commercial SolutionsNov 18Sale65.0085655,64048,881Nov 19 05:00 PM
KEEFE MICHELLEPres., Commercial SolutionsNov 17Sale62.6580050,12049,643Nov 19 05:00 PM
ADVENT INTERNATIONAL CORP/MA10% OwnerSep 17Sale59.263,766,281223,189,81218,647,036Sep 21 09:56 PM
ADVENT INTERNATIONAL CORP/MA10% OwnerSep 17Sale59.263,766,281223,189,81218,647,036Sep 21 09:56 PM
ADVENT INTERNATIONAL CORP/MA10% OwnerSep 17Sale59.263,766,281223,189,81218,647,036Sep 21 09:55 PM
Allen TomDirectorSep 17Sale59.263,766,281223,189,81218,647,036Sep 21 09:55 PM
ADVENT INTERNATIONAL CORP/MA10% OwnerSep 17Sale59.263,766,281223,189,81218,647,036Sep 21 09:55 PM
Maldonado John L.DirectorSep 17Sale59.263,766,281223,189,81218,647,036Sep 21 09:54 PM
ADVENT INTERNATIONAL CORP/MA10% OwnerSep 17Sale59.263,766,281223,189,81218,647,036Sep 21 09:54 PM
ADVENT INTERNATIONAL CORP/MA10% OwnerSep 17Sale59.263,766,281223,189,81218,647,036Sep 21 09:53 PM
THOMAS H. LEE ADVISORS, LLCDirectorSep 17Sale59.263,232,987191,586,81016,006,677Sep 21 05:39 PM
THOMAS H. LEE ADVISORS, LLCDirectorSep 17Sale59.2673243,3781,005Sep 21 05:39 PM
THOMAS H. LEE ADVISORS, LLCDirectorSep 17Sale59.263,232,987191,586,81016,006,677Sep 21 05:30 PM
THOMAS H. LEE ADVISORS, LLCDirectorSep 17Sale59.2673243,3781,005Sep 21 05:30 PM
Macdonald AlistairChief Executive OfficerAug 03Sale65.0710,289669,464246,687Aug 04 05:06 PM
Macdonald AlistairChief Executive OfficerJul 15Option Exercise16.0637,868608,160280,088Jul 17 05:03 PM
Macdonald AlistairChief Executive OfficerJul 15Sale60.1437,8682,277,495261,154Jul 17 05:03 PM
Macdonald AlistairChief Executive OfficerJul 14Option Exercise10.575,17354,679266,327Jul 15 05:03 PM
Macdonald AlistairChief Executive OfficerJul 14Sale58.685,173303,553261,154Jul 15 05:03 PM
Macdonald AlistairChief Executive OfficerJul 13Option Exercise10.573,65538,633264,809Jul 15 05:03 PM
Macdonald AlistairChief Executive OfficerJul 13Sale58.213,655212,747261,154Jul 15 05:03 PM
Dineen John M.DirectorJul 06Buy59.118,691513,72517,426Jul 08 05:04 PM
KEEFE MICHELLEPres., Commercial SolutionsJul 06Sale59.111,50088,66550,443Jul 08 05:06 PM
KEEFE MICHELLEPres., Commercial SolutionsMay 20Sale60.002,500150,00051,943May 21 05:01 PM
Parks RobertEVP, Chief Accounting OfficerApr 20Sale49.653,588178,14412,450Apr 21 07:04 PM
Meggs Jason M.Chief Financial OfficerMar 20Buy36.743,555130,61363,829Mar 23 05:04 PM
COLVIN PAULPres., Clinical SolutionsMar 19Buy36.651,30047,64526,855Mar 23 05:06 PM
Meggs Jason M.Chief Financial OfficerMar 05Option Exercise0.005,094068,923Apr 15 06:39 PM
Macdonald AlistairChief Executive OfficerMar 05Option Exercise0.0031,2580248,937Apr 15 06:55 PM
NRC National Research Corporation daily Stock Chart
NRC [NASD]
National Research Corporation
Index- P/E34.13 EPS (ttm)1.47 Insider Own2.20% Shs Outstand25.22M Perf Week-6.33%
Market Cap1.24B Forward P/E- EPS next Y- Insider Trans-13.63% Shs Float13.45M Perf Month-7.92%
Income37.70M PEG2.63 EPS next Q- Inst Own42.10% Short Float1.27% Perf Quarter-9.32%
Sales131.10M P/S9.49 EPS this Y18.00% Inst Trans-0.28% Short Ratio6.06 Perf Half Y-15.54%
Book/sh2.25 P/B22.22 EPS next Y- ROA32.00% Target Price- Perf Year-21.40%
Cash/sh0.88 P/C56.83 EPS next 5Y13.00% ROE87.30% 52W Range34.00 - 71.35 Perf YTD-24.17%
Dividend- P/FCF71.52 EPS past 5Y11.30% ROI51.40% 52W High-29.93% Beta0.72
Dividend %- Quick Ratio1.50 Sales past 5Y5.30% Gross Margin63.70% 52W Low47.06% ATR2.04
Employees464 Current Ratio1.50 Sales Q/Q3.10% Oper. Margin34.00% RSI (14)38.88 Volatility4.46% 3.78%
OptionableNo Debt/Eq0.56 EPS Q/Q18.30% Profit Margin28.70% Rel Volume1.61 Prev Close49.19
ShortableYes LT Debt/Eq0.49 Earnings- Payout27.90% Avg Volume28.30K Price50.00
Recom3.00 SMA20-8.05% SMA50-5.51% SMA200-6.34% Volume45,514 Change1.65%
Dec-02-20 10:15PM  
Nov-23-20 01:06AM  
Nov-05-20 09:00AM  
Nov-03-20 05:00PM  
Oct-26-20 01:03PM  
Sep-28-20 12:05PM  
Aug-31-20 03:31PM  
Aug-25-20 09:00AM  
Aug-24-20 05:00PM  
04:30PM  
04:00PM  
Aug-05-20 12:49PM  
Aug-04-20 05:00PM  
Jul-28-20 09:00AM  
Jul-22-20 04:26PM  
Jun-22-20 03:17PM  
May-08-20 08:48AM  
May-05-20 05:00PM  
Apr-21-20 03:03PM  
Apr-18-20 09:17AM  
Apr-15-20 12:22PM  
10:30AM  
Mar-26-20 08:36AM  
Mar-13-20 10:33AM  
Mar-09-20 05:20PM  
Feb-20-20 09:06AM  
Feb-11-20 05:00PM  
Feb-07-20 09:00AM  
Feb-05-20 09:00AM  
Jan-28-20 05:15PM  
10:30AM  
Dec-30-19 05:03AM  
Dec-17-19 05:44PM  
Dec-16-19 09:00AM  
Dec-09-19 02:37PM  
Nov-25-19 05:00PM  
Nov-18-19 02:54PM  
Nov-13-19 08:30AM  
Nov-05-19 05:00PM  
Oct-28-19 08:15PM  
Oct-22-19 05:00PM  
Sep-20-19 03:28PM  
Sep-13-19 01:54PM  
Aug-26-19 05:00PM  
Aug-15-19 09:00AM  
Aug-14-19 07:00PM  
Aug-09-19 07:18PM  
Aug-06-19 08:25PM  
05:00PM  
Aug-05-19 12:10PM  
Jul-30-19 10:38AM  
Jul-23-19 05:00PM  
Jun-04-19 09:00AM  
Jun-03-19 05:00PM  
May-30-19 09:00AM  
May-14-19 05:58PM  
May-13-19 09:00AM  
May-08-19 05:23PM  
May-07-19 07:49PM  
05:00PM  
May-02-19 04:17PM  
Apr-22-19 05:18PM  
Mar-01-19 11:03PM  
Feb-26-19 09:00AM  
Feb-13-19 05:00PM  
Feb-12-19 06:04PM  
05:00PM  
Feb-11-19 09:00AM  
Jan-29-19 01:54PM  
Jan-10-19 09:00AM  
Dec-21-18 09:00AM  
Dec-17-18 08:00AM  
Dec-10-18 05:00PM  
Nov-26-18 09:00AM  
Nov-19-18 08:00AM  
Nov-06-18 07:47PM  
05:00PM  
Oct-22-18 05:00PM  
Oct-17-18 09:00AM  
Sep-04-18 05:00PM  
Aug-28-18 02:20PM  
Aug-27-18 08:30AM  
Aug-13-18 07:00AM  
Aug-08-18 07:30AM  
05:09AM  
Aug-07-18 05:00PM  
Jun-25-18 07:01AM  
Jun-14-18 07:00AM  
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions; and health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOANN MDirectorNov 18Option Exercise15.34108,0001,657,080341,810Nov 20 04:02 PM
MARTIN JOANN MDirectorNov 16Sale55.1736,0001,986,253233,810Nov 18 04:19 PM
MARTIN JOANN MDirectorSep 21Option Exercise14.2136,000511,560280,539Sep 23 04:30 PM
Jackson Steven D.PresidentSep 18Sale49.505,905292,29873,791Sep 22 04:16 PM
Jackson Steven D.PresidentSep 02Sale57.855,000289,25079,696Sep 04 04:18 PM
NUNNELLY JOHN NDirectorJul 23Option Exercise31.6312,787404,39439,681Jul 27 04:43 PM
MARTIN JOANN MDirectorJul 23Sale60.0019,8531,191,180254,539Jul 27 04:38 PM
NUNNELLY JOHN NDirectorJul 23Sale60.105,926356,16426,894Jul 27 04:43 PM
MARTIN JOANN MDirectorJul 17Sale60.001106,600274,392Jul 21 04:23 PM
MARTIN JOANN MDirectorJul 15Sale60.0014840274,502Jul 17 04:10 PM
Karas Kevin RSVP Finance, CFO, Treas & SecyJun 05Option Exercise14.5020,088291,27624,088Jun 09 06:01 PM
Karas Kevin RSVP Finance, CFO, Treas & SecyJun 05Sale57.9513,576786,6754,000Jun 09 06:01 PM
MARTIN JOANN MDirectorJun 05Sale60.00231,380275,016Jun 09 05:59 PM
MOWRY BARBARADirectorMay 15Option Exercise14.9536,000538,20042,902May 19 04:10 PM
MARTIN JOANN MDirectorFeb 28Option Exercise11.7872,000847,800290,455Mar 03 04:49 PM
Amandla MK Trust10% OwnerFeb 14Sale70.113,000210,3326,421,545Feb 19 04:36 PM
Amandla MK Trust10% OwnerFeb 07Sale70.251,500105,3756,424,545Feb 10 04:09 PM
Amandla MK Trust10% OwnerFeb 06Sale70.0330021,0106,426,045Feb 10 04:09 PM
Amandla MK Trust10% OwnerFeb 04Sale70.1322,1601,554,1526,426,345Feb 06 04:23 PM
Amandla MK Trust10% OwnerJan 31Sale70.0821,3501,496,2176,448,505Feb 04 04:11 PM
Amandla MK Trust10% OwnerJan 28Sale70.059,252648,0576,469,855Jan 30 04:51 PM
Amandla MK Trust10% OwnerJan 27Sale70.041,00970,6746,479,107Jan 28 04:31 PM
Amandla MK Trust10% OwnerJan 24Sale70.094,635324,8786,480,116Jan 28 04:31 PM
Amandla MK Trust10% OwnerJan 23Sale70.054,930345,3526,484,751Jan 24 04:34 PM
Amandla MK Trust10% OwnerJan 22Sale70.112,900203,3086,489,681Jan 24 04:34 PM
Amandla MK Trust10% OwnerJan 10Sale68.0020013,6006,492,581Jan 14 04:19 PM
Amandla MK Trust10% OwnerJan 09Sale68.155,076345,9166,492,781Jan 10 04:29 PM
Amandla MK Trust10% OwnerJan 08Sale68.041,20081,6476,497,857Jan 10 04:29 PM
Amandla MK Trust10% OwnerJan 07Sale68.162,825192,5466,499,057Jan 08 04:33 PM
Amandla MK Trust10% OwnerJan 06Sale68.365,797396,3046,501,882Jan 08 04:33 PM
Hays Michael D.CEOJan 03Option Exercise6.3026,481166,83039,563Jan 07 04:50 PM
Amandla MK Trust10% OwnerDec 23Sale68.0510,000680,5256,507,679Dec 26 04:51 PM
CRL Charles River Laboratories International, Inc. daily Stock Chart
CRL [NYSE]
Charles River Laboratories International, Inc.
Index- P/E39.58 EPS (ttm)6.00 Insider Own0.70% Shs Outstand49.70M Perf Week3.15%
Market Cap11.69B Forward P/E26.99 EPS next Y8.80 Insider Trans-14.96% Shs Float49.00M Perf Month-4.75%
Income301.50M PEG2.94 EPS next Q2.10 Inst Own96.30% Short Float1.49% Perf Quarter16.02%
Sales2.82B P/S4.14 EPS this Y13.30% Inst Trans0.24% Short Ratio2.25 Perf Half Y28.31%
Book/sh38.17 P/B6.22 EPS next Y12.05% ROA5.90% Target Price259.87 Perf Year64.08%
Cash/sh4.95 P/C47.92 EPS next 5Y13.46% ROE17.40% 52W Range95.58 - 257.88 Perf YTD55.42%
Dividend- P/FCF26.18 EPS past 5Y13.40% ROI8.50% 52W High-7.93% Beta1.11
Dividend %- Quick Ratio1.20 Sales past 5Y15.10% Gross Margin36.70% 52W Low148.40% ATR6.00
Employees17100 Current Ratio1.40 Sales Q/Q11.30% Oper. Margin14.60% RSI (14)53.25 Volatility1.91% 2.39%
OptionableYes Debt/Eq1.06 EPS Q/Q38.60% Profit Margin10.70% Rel Volume0.66 Prev Close234.99
ShortableYes LT Debt/Eq1.04 EarningsOct 29 BMO Payout0.00% Avg Volume326.01K Price237.42
Recom1.80 SMA200.82% SMA501.54% SMA20025.73% Volume215,226 Change1.03%
Sep-10-20Upgrade Jefferies Hold → Buy $254
Jul-01-20Upgrade BofA Securities Neutral → Buy $192
May-13-20Upgrade UBS Neutral → Buy $177 → $200
Apr-21-20Downgrade Jefferies Buy → Hold $139
Mar-27-20Upgrade Morgan Stanley Equal-Weight → Overweight $152
Mar-02-20Initiated Deutsche Bank Buy $190
Feb-18-20Upgrade Wolfe Research Peer Perform → Outperform
Jan-10-20Upgrade Goldman Neutral → Buy $143 → $179
Jan-08-20Initiated Wells Fargo Overweight $180
Jan-07-20Initiated Citigroup Buy $185
Oct-18-19Downgrade BofA/Merrill Buy → Neutral $150
Jun-10-19Initiated SVB Leerink Outperform $155
Apr-30-19Resumed Evercore ISI Outperform $160
Dec-14-18Initiated Deutsche Bank Buy
Oct-09-18Initiated UBS Neutral
Aug-23-18Upgrade Raymond James Mkt Perform → Outperform
Jul-17-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-15-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
Feb-14-18Upgrade SunTrust Hold → Buy
Jan-22-18Downgrade SunTrust Buy → Hold
Nov-27-20 12:43AM  
Nov-20-20 03:07PM  
Nov-19-20 12:45PM  
Nov-12-20 08:00AM  
Nov-09-20 08:30AM  
Nov-05-20 09:15AM  
Nov-03-20 12:45PM  
Nov-01-20 08:20AM  
Oct-30-20 04:31AM  
Oct-29-20 09:00PM  
07:00AM  
Oct-28-20 12:26PM  
Oct-27-20 06:03PM  
Oct-26-20 06:53AM  
Oct-22-20 12:34PM  
12:10PM  
Oct-18-20 09:00PM  
Oct-17-20 12:19AM  
Oct-16-20 09:15AM  
Oct-13-20 08:30AM  
Oct-07-20 12:45PM  
Sep-26-20 09:51AM  
Sep-23-20 11:49AM  
Sep-21-20 02:52PM  
Sep-15-20 04:03PM  
03:11PM  
02:25PM  
11:36AM  
Sep-13-20 08:00PM  
08:00PM  
Sep-09-20 09:35AM  
Sep-08-20 08:30AM  
Aug-31-20 08:59AM  
Aug-28-20 11:20AM  
Aug-07-20 02:00AM  
Aug-05-20 05:00PM  
09:05AM  
07:53AM  
07:21AM  
07:00AM  
Aug-04-20 05:53PM  
05:39PM  
09:41AM  
09:07AM  
Jul-31-20 12:32PM  
Jul-29-20 12:33PM  
Jul-24-20 07:39PM  
Jul-22-20 09:19AM  
Jul-20-20 12:10PM  
Jul-15-20 04:42PM  
Jul-14-20 08:30AM  
Jul-13-20 05:03PM  
Jul-09-20 03:24PM  
Jun-15-20 09:59AM  
Jun-11-20 10:05AM  
09:02AM  
Jun-10-20 10:25AM  
Jun-03-20 02:46AM  
Jun-02-20 08:00AM  
07:58AM  
Jun-01-20 08:00AM  
May-30-20 10:54PM  
11:42AM  
May-28-20 11:00AM  
May-21-20 07:13AM  
May-09-20 09:12AM  
May-08-20 12:31AM  
May-07-20 08:25AM  
07:00AM  
Apr-30-20 12:34PM  
Apr-29-20 12:08PM  
Apr-20-20 03:24PM  
Apr-19-20 03:54PM  
Apr-16-20 08:40AM  
08:30AM  
Mar-30-20 08:30AM  
Mar-25-20 06:26AM  
Mar-22-20 10:56PM  
Mar-10-20 08:30AM  
Mar-04-20 08:00AM  
Feb-14-20 09:31AM  
Feb-13-20 07:11AM  
06:37AM  
Feb-12-20 12:00PM  
10:30AM  
09:15AM  
Feb-11-20 09:19AM  
08:25AM  
07:00AM  
Feb-06-20 09:18AM  
Feb-05-20 08:44AM  
Feb-04-20 12:30PM  
Jan-22-20 07:46AM  
Jan-21-20 04:30PM  
09:11AM  
Jan-19-20 08:16AM  
Jan-17-20 03:34PM  
09:15AM  
Jan-16-20 08:00AM  
Jan-15-20 12:10PM  
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company has a strategic partnership with PathoQuest SAS to establish a next generation sequencing based testing laboratory. Charles River Laboratories International, Inc. is based in Wilmington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LaPlume Joseph WEVP, Corp Strategy & DevelopNov 04Option Exercise123.736,739833,84118,095Nov 05 11:46 AM
LaPlume Joseph WEVP, Corp Strategy & DevelopNov 04Sale250.286,7391,686,62711,356Nov 05 11:46 AM
Barbo William DCorporate Executive VP & CCONov 03Sale236.292,150508,0159,821Nov 05 03:51 PM
WALLMAN RICHARD FDirectorNov 02Buy233.246,0501,411,1046,050Nov 03 01:21 PM
WALLMAN RICHARD FDirectorNov 02Buy232.961,150267,90231,715Nov 03 01:21 PM
FOSTER JAMES CChairman, President and CEONov 02Sale232.3822,0005,112,267186,777Nov 03 04:05 PM
MASSARO GEORGEDirectorSep 14Sale219.911,943427,2849,441Sep 15 05:47 PM
Girshick BirgitCorporate Executive VPAug 20Sale213.51933199,20522,852Aug 21 10:48 AM
CHUBB STEPHEN DDirectorAug 18Sale217.651,000217,65137,657Aug 19 02:48 PM
Smith David RossCorporate Executive VP & CFOAug 07Option Exercise144.673,304477,99024,071Aug 10 04:18 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerAug 07Option Exercise111.413,441383,3535,855Aug 10 03:20 PM
Kochevar Deborah TurnerDirectorAug 07Sale216.242,319501,4676,728Aug 11 10:39 AM
FOSTER JAMES CChairman, President and CEOAug 07Sale217.4924,0005,219,771210,777Aug 10 04:25 PM
Smith David RossCorporate Executive VP & CFOAug 07Sale216.543,304715,44420,767Aug 10 04:18 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerAug 07Sale216.603,456748,5552,399Aug 10 03:20 PM
MASSARO GEORGEDirectorMay 22Sale173.40941163,16811,884May 26 02:37 PM
BERTOLINI ROBERT JDirectorMay 20Option Exercise52.293,530184,58432,664May 21 11:36 AM
BERTOLINI ROBERT JDirectorMay 20Sale174.583,530616,26329,134May 21 11:36 AM
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 18Sale174.6535061,1289,637May 19 04:18 PM
FOSTER JAMES CChairman, President and CEOMay 18Sale175.0017,4353,051,125229,894May 19 04:14 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 15Option Exercise80.486,350511,04525,405May 19 04:18 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 15Sale168.2615,4182,594,1709,987May 19 04:18 PM
Girshick BirgitCorporate Executive VPMay 12Sale165.74780129,27721,837May 13 08:18 AM
FOSTER JAMES CChairman, President and CEOMay 11Sale162.5317,4462,835,433249,329May 13 11:02 AM
Smith David RossCorporate Executive VP & CFOMay 07Sale150.001,884282,60018,591May 08 10:48 AM
Barbo William DCorporate Executive VP & CCOMar 05Option Exercise102.5612,4671,278,67730,201Mar 06 03:50 PM
Barbo William DCorporate Executive VP & CCOMar 05Sale164.3513,9662,295,30016,235Mar 06 03:50 PM
CHUBB STEPHEN DDirectorFeb 27Option Exercise55.177,170395,57242,005Feb 28 10:28 AM
CHUBB STEPHEN DDirectorFeb 27Sale160.892,464396,43739,541Feb 28 10:28 AM
FOSTER JAMES CChairman, President and CEOFeb 26Option Exercise73.7025,1241,851,639311,899Feb 27 02:45 PM
Smith David RossCorporate Executive VP & CFOFeb 26Option Exercise73.704,188308,65624,663Feb 27 02:48 PM
FOSTER JAMES CChairman, President and CEOFeb 26Sale162.2525,1244,076,411286,775Feb 27 02:45 PM
Smith David RossCorporate Executive VP & CFOFeb 26Sale162.264,188679,53520,475Feb 27 02:48 PM
Smith David RossCorporate Executive VP & CFOFeb 24Option Exercise98.028,211804,86029,065Feb 25 11:29 AM
FOSTER JAMES CChairman, President and CEOFeb 24Option Exercise97.8044,3034,332,960333,349Feb 26 10:15 AM
FOSTER JAMES CChairman, President and CEOFeb 24Sale167.833,000503,490750Feb 26 10:15 AM
FOSTER JAMES CChairman, President and CEOFeb 24Sale166.7044,3037,385,433289,046Feb 26 10:15 AM
Smith David RossCorporate Executive VP & CFOFeb 24Sale166.728,2111,368,95320,854Feb 25 11:29 AM
MILNE GEORGE M JRDirectorFeb 18Option Exercise55.177,170395,57234,207Feb 19 10:41 AM
MILNE GEORGE M JRDirectorFeb 18Sale176.077,1701,262,43027,037Feb 19 10:41 AM
WALLMAN RICHARD FDirectorFeb 14Option Exercise52.293,530184,58432,897Feb 14 05:10 PM
WALLMAN RICHARD FDirectorFeb 14Sale174.293,530615,25829,367Feb 14 05:10 PM
BERTOLINI ROBERT JDirectorFeb 13Option Exercise55.177,170395,57235,045Feb 14 12:24 PM
WALLMAN RICHARD FDirectorFeb 13Option Exercise55.177,170395,57236,537Feb 14 05:07 PM
FOSTER JAMES CChairman, President and CEOFeb 13Sale171.9015,0002,578,440298,064Feb 14 03:06 PM
Girshick BirgitCorporate Executive VPFeb 13Sale172.05900154,84523,714Feb 14 09:43 AM
Smith David RossCorporate Executive VP & CFOFeb 13Sale170.294,500766,31921,978Feb 13 07:08 PM
WALLMAN RICHARD FDirectorFeb 13Sale172.027,1701,233,39129,367Feb 14 05:07 PM
BERTOLINI ROBERT JDirectorFeb 13Sale170.417,1701,221,81927,875Feb 14 12:24 PM
Barbo William DCorporate Executive VP & CCOFeb 13Sale172.116,9011,187,69918,931Feb 14 12:01 PM
JOHST DAVID PCorporate Executive VPDec 09Option Exercise76.6724,6601,890,682237,514Dec 11 10:36 AM
JOHST DAVID PCorporate Executive VPDec 09Sale144.2124,6603,556,341212,854Dec 11 10:36 AM
Girshick BirgitCorporate Executive VPDec 09Sale145.551,051152,97217,715Dec 10 05:00 PM
Girshick BirgitCorporate Executive VPDec 09Sale144.932,874416,51618,766Dec 10 04:58 PM
Girshick BirgitCorporate Executive VPDec 09Sale144.212,420348,99321,640Dec 10 04:55 PM
TENX Tenax Therapeutics, Inc. daily Stock Chart
TENX [NASD]
Tenax Therapeutics, Inc.